EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The New Era of Pneumococcal Vaccination in Adults: What Is Next?

Lale Ozisik iD

Vaccines · 07.05.2025 · 13 (5) · 498

DOI: 10.3390/vaccines13050498 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 07.05.2025. Verfasst von Lale Ozisik. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Streptococcus pneumoniae remains the leading cause of community-acquired pneumonia in adults and bacterial meningitis in children worldwide. In addition to pneumonia, invasive pneumococcal diseases (IPDs), such as bacteremia and meningitis, pose a significant burden, particularly among older adults and individuals with underlying comorbidities. These diseases lead to substantial morbidity and mortality. Pneumococcal vaccination has been a cornerstone of disease prevention, reducing incidence and antimicrobial resistance. Recent advances in understanding S. pneumoniae epidemiology, genomic diversity, and the real-world impact of conjugate vaccines have driven the development and licensure of new-generation pneumococcal vaccines with expanded serotype coverage. Introducing 15-valent (PCV15), 20-valent (PCV20), and 21-valent (PCV21) conjugate vaccines has reshaped pneumococcal immunization strategies, particularly in adults, replacing previous sequential vaccine recommendations in many settings. In parallel, emerging epidemiological data and shifts in pneumococcal serotype distribution continue to influence vaccine policy decisions and immunization guidelines worldwide. In light of these advancements, adult pneumococcal vaccination recommendations continuously evolve to enhance protection in high-risk populations and optimize long-term immunity. This review provides an updated overview of the pneumococcal disease burden, the evolution of pneumococcal vaccines, and the latest immunization strategies in an expanding vaccine landscape. Additionally, we discuss future directions in pneumococcal vaccine development and the potential impact of novel vaccination approaches on public health outcomes.

Schlagwörter

Stichwörter der Autor:innen

15-valent pneumococcal conjugate vaccine20-valent pneumococcal conjugate vaccine21-valent pneumococcal conjugate vaccinePCV15PCV20PCV21Streptococcus pneumoniaeadult vaccinationpneumococcal diseasepneumococcal vaccinepneumococcal vaccine recommendations

Autor:innen und Institutionen

  • Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye.
  • Department of Vaccinology, Vaccine Institute, Hacettepe University, Ankara 06100, Türkiye.

ORCID-Profile: Lale Ozisik

Zitieren

APA

Ozisik, L. (2025). The New Era of Pneumococcal Vaccination in Adults: What Is Next?. Vaccines, 13(5), 498. https://doi.org/10.3390/vaccines13050498

Vancouver

Ozisik L. The New Era of Pneumococcal Vaccination in Adults: What Is Next?. Vaccines. 2025;13(5):498. doi:10.3390/vaccines13050498

BibTeX
@article{Ozisik2025,
  author = {Ozisik, Lale},
  title = {The New Era of Pneumococcal Vaccination in Adults: What Is Next?},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {5},
  pages = {498},
  doi = {10.3390/vaccines13050498}
}
Kostenlos starten →